BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aimago Announces FDA Clearance of Its Next-Generation Perfusion Assessment Camera


10/4/2012 7:19:43 AM

LAUSANNE, SWITZERLAND--(Marketwire - Oct 3, 2012) - Aïmago SA, a Swiss medical device company, announces FDA 510(k) clearance of its award-winning, next-generation perfusion camera. The tablet-based Aïmago EasyLDI greatly simplifies perfusion assessment; already CE-marked, it is in active use in several leading European plastic & reconstructive surgery, burn care and wound healing centers.

Aïmago''s EasyLDI provides surgeons and nurses with a highly intuitive, non-invasive, repeatable and user-independent diagnostic imaging tool to objectively identify poorly perfused tissue. This clinically relevant information empowers surgeons to reduce the risk of skin necrosis and delayed healing, thereby leading to better and earlier decision-making for a range of surgical procedures.

Enhanced, Real-Time LDI Brings Numerous Benefits

Aïmago''s perfusion camera uses the established Laser Doppler Imaging (LDI) technology. The skin is illuminated by laser light, part of which is reflected by moving red blood cells, which, through the Doppler effect, cause a shift in the wavelength of the laser light detected by the LDI camera. Aïmago has enhanced this LDI technology to create a fast, intuitive and accurate device, providing tangible benefits:

Compact, ergonomic design for easy, fast and intuitive use like a digital camera

Contactless and non-invasive - no injection of fluorescent dyes and contrast agents

Continuous real-time imaging with no delay or need for repeated dye injections

Usable under ambient lighting, both inside & outside the operating room, and bedside

For use by surgeons and nurses, without assistance of an anaesthetist or extra personnel

Michael Friedrich, co-founder and CEO of Aïmago, commented, "Our technology and design represent a new paradigm for skin perfusion assessment, with the potential to optimize surgeons'' decision-making and greatly facilitate the achievement of successful outcomes, thereby reducing overall cost-of-care. Having attained US clearance, we are confident that EasyLDI will soon become the new reference for perfusion assessment."

More detailed information about EasyLDI, including the technology, product specifications and clinical applications, is available at www.aimago.com.

About Aïmago

Aïmago is a privately held, investor-backed medical device company founded in 2008 as a spin-off from the EPFL (Swiss Federal Institute of Technology in Lausanne) and specializing in perfusion assessment in various clinical settings. Aïmago''s revolutionary EasyLDI microcirculation camera enjoys patent protection, is already in use at several hospitals in the EU, and is slated for launch in the US in 2012. The company has won several awards, including the CTI MedTech Award 2011 from the Swiss government and the W.A. de Vigier Award for best Swiss start-up. More information is available at www.aimago.com.

Contact:

Aimago SA

Michael Friedrich

Co-Founder and CEO

Parc Scientifique EPFL, PSE-D, 1015 Lausanne, Switzerland

michael.friedrich@aimago.com

www.aimago.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES